Vaccine developments

Nature Medicine

Volumn 4, Issue 5 SUPPL., 1998, Pages 515-519

  Liu, Margaret A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE; VIRUS VECTOR;

DRUG RESEARCH; EXPRESSION VECTOR; GENE SEQUENCE; HUMAN; IMMUNE RESPONSE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; VACCINATION;

EID: 0031960459     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0598supp-515     Document Type: Review

References (53)

1. Levine, M.M., Woodrow, G.C., Kaper, J.B. & Cobon, G.S. New generation vaccines. Second edn (Marcel Dekker, Inc., New York, 1997).
2. Fenner, F., Henderson, D.A., Arita, L., Jezek, Z. & Ladnyi, I.D. Smallpox and its eradication (World Health Organization, Geneva, 1988).
3. Jenner, E. An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow pox. London, 1798, in Classics of Medicine and Surgery (ed. Camac, C.N.B.) 213-240 (Dover, New York, 1959).
4. Pasteur, L., Chamberland, C.-E. & Roux, E. Sur la vaccination charbonneuse. CR Acad Sci, Paris 92, 1378-1383 (1881).
5. Pasteur, L. Une statistique au sujet de la vaccination préventive contre le charbon, portant sur quatre-vingt-cinq-mille animaux. CR Acad Sci, Paris 95, 1250-1252 (1882).
6. Calmette, A. La vaccination preventive contre la tuberculose par le BCG (Masson, Paris, 1927).
7. Maassab, H.F. & DeBorde, D.C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3, 355-371 (1985).
8. Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. & Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941 (1992).
9. Almond, N. et al. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345, 1342-1344 (1995).
10. Lohman, B.L. et al. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68, 7021-7091 (1994).
11. Ruprecht, R.M. et al. "Attenuated" simian immunodeficiency virus in macaque neonates. AIDS Res. Hum Retroviruses 12, 459-460 (1996).
12. Baba, T.W. et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820-1825 (1995).
13. Treanor, J.J. et al. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr. Infect. Dis. J. 14, 301-307 (1995).
14. Rennels, M.B. et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 97, 7-13 (1996).
15. Smith, G.L. & Moss, B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 25, 21-28 (1983).
16. Jones, L., Ristow, S., Yilma, T. & Moss, B. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene [letter]. Nature 319, 543 (1986).
17. Cooney, E.L. et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337, 567-572 (1991).
18. Rooney, J.F., Wohlenberg, C., Cremer, K.J., Moss, B. & Notkins, A.L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J. Virol. 62, 1530-1534 (1988).
19. Kundig, T.M., Kalberer, C.P., Hengartner, H. & Zinkernagel, R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11, 1154-1158 (1993).
20. Hanke, T. et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439 (1998).
21. Fries, L.F. et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14, 428-434 (1996).
22. Frolov, I. et al. Alphavirus-based expression vectors: Strategies and applications. Proc. Natl. Acad. Sci. U S A 93, 11371-11377 (1996).
23. Xiong, C. et al. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243, 1188-1191 (1989).
24. Davis, N.L., Brown, K.W. & Johnston, R.E. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70, 3781-3787 (1996).
25. Caley, I.J. et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71, 3031-3038 (1997).
26. Sizemore, D.R., Branstrom, A.A. & Sadoff, J.C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270, 299-302 (1995).
27. Darji, A. et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765-775 (1997).
28. + T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int. Immunol. 7, 797-805 (1995).
29. Dietrich, G. et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nature Biotechnol. 16, 181-185 (1998).
30. Hoth, D.F., Bolognesi, D.P., Corey, L. & Vermund, S.H. HIV vaccine development: a progress report. Ann Intern. Med. 8, 603-611 (1994).
31. Clements-Mann, M.L. et al. HIV-1 immune responses induced by canarypox (ALVAC) gp-160 MN, SF2 rgp120, or both vaccines in seronegative adults. J. of Infect. Dis. (In press).
32. Graham, B.S. & Wright, P.F. Candidate AIDS vaccines. N. Engl. J. Med. 333, 1331-1339 (1995).
33. Murphy, T.V. et al. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA 269, 246-248 (1993).
34. Hofmann, J. et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N. Engl. J. Med. 333, 481-486 (1995).
35. 26AI. Vaccine 15, 1314-1318 (1997).
36. Gupta, R.K. & Siber, G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13, 1263-1276 (1995).
37. Cox, J.C. & Coulter, A.R. Adjuvants - a classification and review of their modes of action. Vaccine 15, 248-256 (1997)
38. Gupta, R.K., Chang, A.C., Griffin, P., Rivera, R. & Siber, G.R. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 14, 1412-1416 (1996).
39. Anderson, J.M. & Shive, M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 28, 5-24 (1997).
40. Tamura, S. et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12, 419-426 (1994).
41. Glenn, G.M., Rao, M., Matyas, G.R. & Alving, C.R. Skin immunization made possible by cholera toxin. Nature 391, 851 (1998).
42. Robbins, J.B., Schneerson, R. & Szu, S.C. Hypothesis: how licensed vaccines confer protective immunity. Adv. Exp. Med. Biol. 397, 169-182 (1996).
43. Haq, T.A., Mason, H.S., Clements, J.D. & Arntzen, C.J. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 268, 714-716 (1995).
44. Mason, H.S. et al. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA 93, 5335-5340 (1996).
45. Arakawa, T., Chong, D.K.X. & Langridge, W.H.R. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nature Biotechnol. 16, 292-298 (1998).
46. Donnelly, J.J., Ulmer, J.B., Shiver, J.W. & Liu, M.A. DNA vaccines. Annu. Rev. Immunol. 15, 617-648 (1997).
47. Martinon, F. et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23, 1719-1722 (1993).
48. Ward, G., Reider, E. & Mason, P.W. Plasmid DNA encoding replicating foot and mouth disease virus genomes induces antiviral immune responses in swine. Journal of Virology 71, 7442-7447 (1997).
49. Hariharan, M.J. et al. DNA immunization against herpes simplex virus: enhanced efficacy using a sindbis virus-based vector. J. Virol. 72, 950-958 (1998).
50. Macatonia, S.E., Patterson, S. & Knight, S.C. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 74, 399-406 (1991).
51. Nestle, F.O. et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332 (1998).
52. Fleischmann, R.D. et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496-512 (1995).
53. Orme, I.M. Prospects for new vaccines against tuberculosis. Trends In Microbiology 3, 401-404 (1995).